#Japan #Osaka #Ono Pharmaceutical #Revenir #Congruence Therapeutics

Ono Pharmaceutical and Congruence Therapeutics Collaboration

Ono Pharmaceutical Co., Ltd., based in Osaka, has taken a significant step in advancing cancer treatment through a collaboration with Congruence Therapeutics, headquartered in Montreal. This partnership aims to utilize Congruence's advanced drug discovery platform, Revenir™, to develop innovative small molecule correctors targeting various protein defects associated with cancer.

The agreement allows Congruence to leverage its proprietary technology to discover and develop these potential therapies, while Ono secures exclusive rights for further development, manufacturing, and commercialization globally. According to the terms of the collaboration, Congruence will be compensated with an upfront payment in addition to research expenses, milestone payments tied to the progress of the research and development, plus tiered royalties based on net sales.

During the announcement, Seishi Katsumata, Executive Director for Discovery Research at Ono, expressed optimism about the collaboration's potential: "We believe this collaboration with Congruence may help generate novel small molecule correctors for validated targets in the oncology area by leveraging their own technologies in protein dynamics and computational biology, leading our development pipeline." This reflects Ono's commitment to delivering groundbreaking drugs to cancer patients as swiftly as possible.

On the other hand, Congruence Therapeutics is excited about the partnership, as they see a strong alignment with Ono's reputation as a leader in drug development, particularly in oncology. Chief Scientific Officer Dr. Sharath Hegde indicated that the Revenir™ platform aims to accelerate the discovery of new therapies targeting crucial areas of research for both companies: "We believe that our Revenir™ platform and capabilities in protein dynamics will help in uncovering novel therapies for significant targets of interest."

What is Revenir™?

Revenir™ is a state-of-the-art computational drug discovery platform that captures the dynamic biophysical changes induced by mutations in proteins. This technology offers unparalleled insights into protein defects and their rectification potential. By analyzing protein conformations and their surface features, Revenir™ can effectively predict small molecule corrections for underlying protein defects. This innovative approach positions Congruence at the forefront of biotechnology, facilitating the design of transformative small molecule correctors aimed at restoring impaired protein functions.

Congruence Therapeutics has positioned itself as a key player within the realm of computational biotechnology, focusing on building a pipeline of drug candidates designed to repair protein function abnormalities. Their scalable Revenir™ platform is essential in identifying novel allosteric and cryptic pockets within proteins, thus facilitating the generation of entirely new chemical entities.

In summary, the partnership between Ono Pharmaceutical and Congruence Therapeutics stands to make significant strides in oncology. By combining Ono's strong track record in drug development with Congruence's advanced computational capabilities, they are well-positioned to tackle some of the most challenging targets in cancer treatment. Both companies are committed to fast-tracking the delivery of effective therapies to patients, showcasing their dedication to innovation in healthcare.